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Abstract: Migraine is a very common disorder characterized by the combination of typical 
headache with associated autonomic symptoms and/or the presence of aura. Considerable 
advances have been made in recent years to understand the pathophysiology of migraine, which 
has led to improved treatment options for the acute migraine attack as well as migraine prophy-
laxis. Unfortunately, preventive treatment is often insufficient to decrease migraine frequency 
substantially or is not well tolerated. Topiramate is an antipileptic drug with a complex mode 
of action which has proven its efficacy and safety in the prophylactic treatment of episodic 
migraine in a number of randomized controlled clinical trials. Topiramate is also effective in 
treating patients with chronic migraine. It has little pharmacological interaction with other drugs 
and is generally well tolerated by patients.
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Introduction
Migraine is the second most common form of headache after episodic tension-type 
headache. Epidemiological studies have documented its high prevalence and high 
socioeconomic impacts. It is ranked by the World Health Organization as number 19 
among all diseases worldwide causing disability.1,2 Migraine is characterized by uni-
lateral location, but may also be bilateral, pulsating, of moderate to severe intensity, 
aggravated by routine physical activity and associated with nausea and/or photophobia 
and phonophobia. Attacks usually last between 4 and 72 hours.3 A typical feature of 
migraine is that headache may change sides from attack to attack in contrast to tri-
geminal autonomic cephalalgias in which the headache in general is side-locked.
Lifetime prevalence is as high as 14%, with a male to female ratio that varies 
for adults from 1:2 to 1:3.1 Current prevalence of migraine was estimated at 10%.2 
Women have more migraine without aura than migraine with aura. The most common 
age of onset of migraine is in the second and third decades of life. The prevalence 
of migraine increases with age until a peak is reached during the fourth decade after 
which the prevalence declines, with a more pronounced decline in women than in 
men.1 Migraine prevalence varies with age. Two different studies investigated the 
prevalence of migraine before the age of 20 and beyond the age 65 years. A Brazilian 
study found a 1-year migraine prevalence of 10.6% with a male to female ratio of 
5.1% to 14.1% in patients older than 65 years.4 The youth part of the Head-HUNT 
study found a 1-year overall prevalence of 7.1% among investigated subjects between 
the ages of 12 and 19 years.5Neuropsychiatric Disease and Treatment 2010:6 18
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In a population-based study 27%6 and 45.8% of migraine 
patients in a tertiary referral center7 have strictly unilateral 
headache with unilateral autonomic features (UAs) such as 
ipsilateral conjunctival injection, ipsilateral tearing, ipsilat-
eral nasal congestion or rhinorrhea, ipsilateral eyelid edema, 
ipsilateral miosis or ptosis, and ipsilateral forehead or facial 
sweating. A recent population-based study demonstrated of 
these migraine patients 43.4% reported to have only 1 UA 
during the migraine attack regularly,6 34.3 % reported to 
have 2, 15.4% had 3, 4.9% had 4, and 2.1% reported to have 
5 UAs during their migraine attack. Migraine patients with 
UAs experienced their head pain strictly more often unilateral 
(38.5%) than non-UA patients (20.1%). These patients with 
UAs also experienced a greater increase in pain intensity dur-
ing a migraine attack than non-UA migraine patients (mean 
visual analog scale: 7.4 vs 5.2), but no reasonable pattern 
was observed in the correlation of the number of UAs to pain 
intensity in this respect.6
Nearly 30% to 40% of migraine patients experience tran-
sient focal neurological symptoms before headaches occur;8–11 
this so-called aura is visual in most cases, but other sensory and 
motor symptoms may occur.12 Aura slowly develops over sev-
eral minutes and usually lasts approximately 15 to 60 minutes. 
Many migraine patients describe a premonitory phase, which 
may begin up to 2 days before the headache itself. Symptoms of 
this premonitory phase are unspecific. Hyper- or hypoactivity, 
dizziness, neck stiffness, craving for food, yawning, or even 
sensitivity for light and sound were described.13
Major goals in migraine therapy are lifting the burden, and 
improving the quality of life by reducing migraine frequency, 
severity, duration and disability during and between attacks 
thus enabling patients a normal function in everyday life 
routines. Even though migraine therapy and migraine 
acceptance has come a long way over the past decade, it still 
remains a frequently undertreated condition.14,15 The treatment 
of migraine consists of three major steps: 1) elimination of 
environmental and psychosocial factors that may worsen or 
contribute to the development of headache, 2) adequate and 
sufficient acute therapy, and 3) prophylactic treatment, which 
should be considered and recommended to patients with high 
attack frequency, severe attack intensity or very disabling aura 
phenomena. Table 1 gives an overview of drugs commonly 
used in migraine therapy and prophylaxis, as well as their 
side effects and contraindications.
In general, a timely start of preventive treatment has to 
be considered in patients suffering from migraine with high 
impact on daily activities and overall functioning. Many dif-
ferent substances were tested in regard to their prophylactic 
effects on migraine. Some proved efficient in multicenter, 
randomized, controlled clinical trials and thus were recom-
mended by current European and US treatment guidelines for 
the standardized, evidence based treatment of migraine.16,17 
One of the latest drugs with proven efficacy in migraine 
prophylaxis is topiramate. Three large, controlled, clinical 
trials have been conducted over recent years. Topiramate is 
a sulfamate-substituted monosaccharide, related to fructose. 
It is rapidly absorbed (peak plasma concentrations about 
2 hours after intake) with a high bioavailability (81% to 95%). 
The major fraction of topiramate is eliminated primarily as 
unchanged drug. It shows linear steady-state pharmacokinet-
ics, and its elimination half-life in monotherapy ranged from 
19 to 25 hours in healthy volunteers after single-dose oral 
administration.18
Topiramate was initially approved in 1995 in the UK as 
adjunctive treatment of partial-onset seizures in adult epi-
lepsy patients.19 Although the different mode of action have 
not yet been conclusively unraveled, there is evidence that 
the antiepileptic potential is not based on its specific impact 
on a singule channel or a particular channel subtype, but on 
several different mechanisms of action. Topiramate blocks 
voltage-dependent sodium and calcium channels.20,21 It also 
inhibits the excitatory glutamate pathway while enhancing 
the inhibitory effect of GABA.22,23 Moreover, it inhibits 
carbonic anhydrase activity.24 The relevant mechanism of 
action responsible for efficient migraine prophylaxis remains 
to be determined.
This review will summarize current knowledge about the 
treatment of migraine with topiramate. A MEDLINE search 
(October 20th, 2009) for articles containing “topiramate” 
and “migraine” was performed and returned 321 articles, of 
which 103 were marked as review articles. The focus will 
be directed on recent randomized, controlled, clinical trials 
on the efficacy and safety of topiramate in prophylactic 
treatment of migraine in general and treatment of chronic 
migraine in particular.
Prophylactic treatment of episodic 
migraine with topiramate
Most migraine patients are treated or treat themselves with 
acute attack/rescue medication. Prophylactic migraine treat-
ment is much more uncommon. Even though as early as 
1966 the prophylactic effect of the unselective beta-blocker 
propranolol was first described in migraine25,26 long before 
a commonly accepted definition of migraine was released 
by the International Headache Society in 1988.27 Several 
international guidelines have been published on treatment Neuropsychiatric Disease and Treatment 2010:6 19
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Table 1 Substances used for migraine treatment recommended by eFNS Guideline on the treatment of migraine16
LR Substance Dose (if not given in mg) Side effects Contraindications
Acute migraine treatment
A ASA 1000 (oral) 1000 (iv) gastrointestinal side effects,  
abdominal pain, clotting  
abnormality, risk of bleeding
gastric ulcer, bleeding diathesis,  
pregnancy (months 7–9)
A ibuprofen 200–800 side effects as for ASA, edema like ASA (less bleeding tendency),  
renal failure, pulmonary embolism
A Naproxen 500–1000 like ibuprofen like ibuprofen
A Acetaminophen/ 
paracetamol
1000 (oral or suppository) liver damage liver and kidney failure
A Diclofenac 50–100 like ibuprofen like ibuprofen
A ASA plus paracetamol  
plus caffeine
250 (oral)  
200–250  
50
see ASA and paracetamol see ASA and paracetamol
B Metamizol 1000 (oral) 1000 (iv) allergic reaction, changes in blood  
count, risk of agranulocytosis in iv  
use risk of hypotension
hematopoietic system disease
B Phenazon 1000 (oral) see paracetamol unknown
B Tolfenamic acid 200 (oral) side effects as for ASA unknown
A Sumatriptan 25, 50, 100 (oral)  
25 (suppository)  
10, 20 (nasal spray)  
6 (subcutaneous)
angina, nausea, distal paresthesia,  
fatigue sensation of cold in  
subcutaneous use – local skin  
reaction at injection site
arterial hypertension (untreated),  
coronary heart disease, peripheral  
artery occlusive disease,  
cerebrovascular disease, multiple  
vascular risk factors, raynaud’s  
disease, pregnancy, lactation, age  
under 18 (except sumatriptan  
nasal spray), severe liver or kidney  
failure, age above 65, simultaneous 
treatment with ergotamine,  
within 2 weeks after break off from  
treatment with a MAO inhibitor
A Zolmitriptan 2.5, 5 (oral)  
2.5, 5 (nasal spray)
see sumatriptan see sumatriptan
A Naratriptan 2.5 (oral) see sumatriptan (probably milder/ 
fewer side effects)
see sumatriptan
A rizatriptan 10 (oral)  
5 mg (when additionally 
on propranolol)
see sumatriptan see sumatriptan
A Almotriptan 12.5 (oral) see sumatriptan (probably milder/  
fewer side effects)
see sumatriptan
A eletriptan 20, 40 (oral)  
80 allowed if 40 not effective
see sumatriptan see sumatriptan
A Frovatriptan 2.5 (oral) see sumatriptan (probably milder/ 
fewer side effects)
see sumatriptan
Prophylactic migraine treatment
A Metoprolol 50–200 oft: fatigue, arterial hypotension  
occ.: sleep disturbances, dizziness
s: hypoglycemia, bronchospasm, 
bradycardia, gastrointestinal side 
effects, impotence
a: AV block, bradycardia, asthma and 
sick sinus syndrome  
r: diabetes mellitus, depression, 
diabetes mellitus, orthostatic 
disregulation
A Propranolol 40–240
    (Continued)Neuropsychiatric Disease and Treatment 2010:6 20
Naegel and Obermann Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Table 1 (Continued)
LR Substance Dose (if not given in mg) Side effects Contraindications
A Flunarizine 5–10 oft: fatigue, weight gain  
occ: gastrointestinal side effects,  
depression  
s: hyperkinesia, tremor, parkinsonism
a: focal dystonia and depression, 
pregnancy and lactation
r: familiar parkinsonism
A Valproic acid 500–1800 oft: fatigue dizziness, tremor  
occ: exanthema, hair loss, weight gain   
s: elevation of liver enzymes/
disturbance in liver function
a: liver failure, pregnancy, alcoholism, 
polycystic ovaries
A Topiramate 25–100 oft: fatigue, cognitive disturbance,  
weight loss, paresthesia  
occ: change in taste, psychosis  
s: glaucoma
a: renal insufficiency, nephrolithiasis, 
glaucoma
B Amitriptyline 50–150 oft: dry mouth, fatigue, dizziness, 
sweating  
occ: constipation, impotence, 
incontinence, restlessness
a: glaucoma, prostatic adenoma and 
hyperplasia  
r: heart insufficiency
B Venlafaxine 2 × 75–150 oft: fatigue, loss of concentration 
s: impotence, arterial hypertension
a: severe hypotension
B Naproxen 2 × 250–500 gastrointestinal side effects a: gastric ulcer, bleedings  
r: asthma bronchiale
B Petasites 2 × 75 occ: burping, gastrointestinal side 
effects  
s: liver disturbances
a: pregnancy and lactation
B Bisoprolol 5–10 see metoprolol and propranolol
C  Gabapentin (1200–1600 mg), Magnesium (24 mmol), Tanacetum parthenium (3 × 6.25 mg), Riboflavin (400 mg), Coenzyme Q10 (300 mg), 
Candesartan (16 mg), Lisinopril (20 mg), Methysergide (4–12 mg)  
Notes: evidence class A indicates the presence of multiple randomized controlled clinical trial; evidence class B indicates one randomized trial exists or multiple uncontrolled 
trials were performed; evidence class C refers to common expert opinion or single case reports.
Abbreviations: ASA, acetylsalicylic acid; AV, atrioventricular; oft, often; occ, occasionally; s, seldom; a, absolute; r, relative; Lr, level of recommendation; MOA, monoamine 
oxidase inhibitor.
indications, choice of drugs, and treatment options and goals. 
Although these guidelines are to some extent diverse, there 
is consensus that the indication for the start of prophylactic 
treatment should be well discussed with the patient and 
patient preference should be considered. The most impor-
tant points in the decision on whether prophylactic therapy 
is required are frequency and severity of migraine and its 
impact on quality of life. Possible problems with acute 
medication should be considered (eg, overuse, adverse events, 
contraindications, absence of efficacy) as well as possible 
side effects and efficacy of prophylactic treatment. Important 
for the compliance of the patient to prophylactic therapy 
is the adjustment of patients’ expectations to an adequate 
level, for example, complete freedom from headache is not 
a realistic goal.25 Appropriate goals of preventive therapy 
are: 1) reduced attack frequency, severity and duration; 
2) improved response to acute attack treatment; 3) improved 
quality of life and reduced disability. In a recent study Lipton 
et al investigated the probable need for preventive therapy 
in the US.28 This was assessed following operational criteria 
defining reasonable starting points of preventive therapy. 
These criteria were developed by an expert panel to provide 
an objectively comparable benchmark. Authors found that 
25.7% met criteria for “offer prevention” and in an additional 
13.1% that prevention should be considered. Just 12.4% 
reported current use of daily preventive migraine medica-
tion. This indicates that preventive treatment still is severely 
underutilized. These figures are similar in France (6%) and 
worse in Latin America (2%).28–30
After some preliminary analyses, and open-label and 
small controlled studies31–34 reported topiramate to be effec-
tive in preventive migraine therapy, three large placebo-
controlled trails (two North American and one European) 
were published in 2004, which investigated the efficacy and 
safety of preventive migraine treatment with topiramate.19,35,36 
All three studies used a similar study design. After 14 days 
washout and a 28-day prospective baseline period, different 
topiramate doses were tested in a 26 (8 + 18)-week double-
blind (DB) phase against placebo. In the two northern 
American trials (MIGR-001 and MIGR-002, with 49 and Neuropsychiatric Disease and Treatment 2010:6 21
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52 participating centers) topiramate target doses of 50, 100 
and 200 mg/day were tested against placebo, and in the 
European trial (MIGR-003 with 61 participating centers) only 
two different daily doses of topiramate (100 and 200 mg/day) 
were tested. In addition to the placebo group a blinded active 
control group receiving propranolol for preventive treatment 
was carried out in the European trial only. Inclusion criteria 
in all three trials were: i) patients aged 12 to 65 years with an 
established history of migraine with or without aura (assessed 
using ICHD-I criteria27) and ii) 3 to 12 migraine headache 
days and iii) not more than 15 headache days (migraine or 
nonmigraine) during the baseline phase. A headache day was 
defined as a calendar day during which a patient experienced 
headache for at least 30 minutes. The 26-week double-blind 
phase started with an 8-week titration period (25 mg/day 
starting dose and weekly increase of 25 mg). In each trial this 
increase was performed up to the previously assigned dose 
or maximal tolerated dose. After titration, the double blind 
period was completed after an 18-week maintenance phase. 
The study drugs were administered in two equally divided 
daily doses. In all three trials patients were permitted to take 
acute/rescue medications. Exclusion criteria were largely 
similar in all trials, including overuse of acute migraine 
therapies, medications potentially interfering with study 
outcome and headaches other than migraine.
The primary efficacy measure in all trials was the 
change of mean monthly (28 days) migraine frequency 
from baseline through the entire DB period. Significance 
was tested between the treatment groups and placebo. 
Frequency was measured with headache diaries using the 
concept of migraine period, defined as any occurrence of 
migraine headache that started, ended or recurred within 
24 hours. Pain lasting longer than 24 hours after its initial 
onset constituted a new, distinct migraine period. The sec-
ondary outcome variables were largely similar in all studies 
as well including time of topiramate action onset, proportion 
of subjects responding to treatment (defined as at least 50% 
monthly migraine frequency reduction), mean change in 
monthly migraine days as well as change in number of days 
per month requiring rescue medication compared to baseline. 
Some trials also reported the change in duration and severity 
of migraine attacks. Due to the similarity in study design 
and chosen endpoints, a pooled analysis with all patients 
from the three trials randomized to topiramate 100 mg/day 
was performed by Bussone et al in 2005.37
Pooling all controlled trials, more than 1500 patients were 
randomized and included in the intent to treat (ITT) cohorts. 
From these, 663 withdrew from trials due to adverse events, 
lack of efficacy, own choice or lost to follow up (220, 228, 
215, respectively) (see Table 2 for details on withdrawal rates). 
Although adverse events had been the most common reason 
for withdrawal in all topiramate groups, patients randomized to 
placebo most often withdrew because of lack of efficacy. In all 
three studies baseline clinical and demographic characteristics 
were well balanced between groups. The results of the different 
trials are similar. All trials showed that prophylactic treatment 
with topiramate reduced migraine frequency considering the 
mean change in monthly migraine periods compared to baseline 
with the 100 mg/day dose. While the North American trials 
showed a reduction in mean monthly migraine frequency for 
the 200-mg/day group, the European trial failed to do so. The 
authors suggested that this was due to the high rate of with-
drawal in this treatment group (79 of 144 patients randomized; 
63 due to adverse events [AE]). A daily dose of 50 mg showed 
a reduction in mean monthly migraine frequency which was 
not significant compared to placebo. In all trials 100 mg/day 
topiramate showed a significant onset of action within the first 
month. Propranolol, used only in the European trial, also showed 
efficacy within the first month of treatment. Interestingly, in all 
groups treated with topiramate (50, 100 or 200 mg) responder 
rate was higher compared to placebo regardless of whether it 
Table 2 Topiramate common interactions
Interacting drug Form of interaction
Phenytoin Decrease of plasma concentration of topiramate
increase plasma level of phenytoin
Carbamazepine Decrease of plasma concentration of topiramate
Digoxin Decrease in digoxin plasma level (seen after a 
single shot of topiramate [found in a single trial])
estrogens Decrease in effectiveness of oral contraception 
(seen in 200 mg, 400 mg and 800 mg daily doses 
of topiramate)
Hydrochlorothiazide increase of topiramate plasma levels; higher 
decrease in plasma potassium levels as usual
Lithium Change of lithium plasma concentration
Metformin reduction of topiramate oral plasma clearance; 
increase of metformin plasma level
Pioglitazone Decrease in plasma levels of pioglitazone and its 
active metabolites
Glibenclamide reduction of glibenclamide plasma levels, reduc-
tion of the systemic bioavailability of some 
glibenclamides active metabolites
Valproic acid Hyperammonemia with or without encephalopa-
thy, in most cases with reduction of signs and 
symptoms after discontinuation of one of both 
drugs
Carbonic anhydrase 
inhibitors
increase of effect on carbonic anhydrase 
inhibitionNeuropsychiatric Disease and Treatment 2010:6 22
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significantly reduced mean migraine frequency. In contrast, 
the reduction in mean rescue medication days was significant 
only in groups in which the primary efficacy measure was also 
significant (MIGR-001: topiramate 100: -1.9 days, topiramate 
200: -2.1 days; MIGR-002: topiramate 100: -2.1 days, topi-
ramate 200–2.2 days; MIGR-003: topiramate 100–1.5 days, 
propranolol: -1.6 days; overall placebo -0.8 to -1.0 days). In 
MIGR-002 change in average duration for 200 mg/day and 
change in pain severity for 100 mg/day was significant.
Some additional information was derived from the pooled 
analysis due to the 3-fold increase in patient numbers. The 
change in monthly migraine frequency was reassessed, 
including number of migraine periods, number of migraine 
attacks, and number of migraine days. All three variables 
showed significant reduction compared to placebo. The high 
number of analyzed patients allowed a gender-specific analy-
sis, which showed that the therapeutic effect was independent 
of gender. The monthly migraine duration was significantly 
changed from baseline by -46.5% compared to -20% in 
placebo group (P  0.05). In summary, there is sufficient 
scientific evidence showing topiramate is effective in reduc-
ing migraine frequency at a dose of 100 mg/day.
Long-term prophylaxis  
with topiramate
Some experts recommend a minimal duration of 6 to 
12 months for preventive migraine therapy before a drug 
holiday should be considered.25 Most patients, however, will 
require a longer treatment period. Clinical trials that assessed 
the efficacy of migraine prevention over more than 1 year are 
scarce.38,39 To demonstrate that topiramate is effective and 
well tolerated when used for preventive migraine therapy up 
to 14 months, an 8-month open label extension (OLE) of the 
two large North American trials (MIGR-001 and MIGR-002) 
was performed.40 To enter this extension period, patients 
were required to have completed the DB phase or to have 
withdrawn after 4 weeks due to lack of efficacy. All eligible 
patients (n = 567, 159 received placebo, 408 on topiramate) 
were titrated to a clinical effective dose over a 7-week period. 
During the OLE phase further decrease in mean monthly 
migraine frequency was observed in subjects who received 
topiramate and in patients who were switched from the 
placebo group. But the slight additional improvement during 
these 8 months appeared not to be significant in the group with 
previous topiramate intake. Similar to the original trials the 
topiramate-associated reduction in mean migraine frequency 
assessed in the group that previously received placebo 
during the DB phase was observed after the first month 
of topiramate therapy. Furthermore, significant reductions 
observed in patients treated with 100 and 200 mg/day topi-
ramate a day were sustained over the 8 months OLE phase. 
The authors concluded that the clinical benefit appears to 
be sustained in patients treated with topiramate over 1 year 
and that there was no loss of efficacy over time, even when 
patients switched from a higher to a lower dose.
In 2007 a randomized, controlled clinical trial introduced 
a novel and very interesting study design. All patients were 
treated with topiramate in an open-label fashion for a period 
of 26 weeks, then randomized into topiramate and placebo 
groups.41 After a 4- to 8-week titration period (starting dose 
25 mg/day topiramate, increase 25 mg/week weekly, target 
dose 100 mg/day) 818 patients entered a 26-week open-label 
(OL) phase with further dose adjustments (range 50 to 
200 mg/day) and received a stable dose for the last 4 weeks 
within this 26-week period. 514 patients (of 559 patients 
that completed the OL phase) entered the following 26-week 
double-blind phase in which patients were randomly assigned 
to continue their dose (n = 255) or switched to placebo 
(n = 259). While in OL phase the most common reason for 
discontinuation was insufficient tolerability (21%), in DB 
phase insufficient efficacy was the most common reason 
(7% in topiramate, 13% in placebo). During the OL phase 
the mean number of migraine days per 4 weeks decreased 
from OL baseline to the last 4 weeks (–3.09 migraine days; 
P  0.0001). After the open label phase the number of 
migraine days (comparing the last 4 weeks of OL with the 
last 4 weeks of DB) increased in both groups as expected. The 
mean increase was greater in the placebo group (1.19 days, 
P  0.0001) than in the topiramate group (0.10, P = 0.5756), 
but it did not return to baseline value (P  0.0001). The 
differences between both groups were statistically significant 
(-1.09, P = 0.0011). The change in number of migraine days 
showed a sharp increase within the first 4 weeks on placebo, 
while the topiramate group showed only a slight increase 
after entering the DB phase. The difference between treat-
ment groups remained significant throughout the whole DB 
phase except between weeks 9 and 16. Duration of migraine 
headaches remained the same in both groups, while headache 
severity did not change in the topiramate group between OL 
and DB but slightly increased in the placebo group. Further-
more, patients in the placebo group had a greater increase 
in days on acute medication from OL than those in the 
topiramate group (mean difference –0.95 days, P = 0.0007). 
To assess health-related quality of life three questionnaires 
were used in this trial. The six-item headache impact test 
(HIT-6)42 showed no significant difference, but differences Neuropsychiatric Disease and Treatment 2010:6 23
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between topiramate and placebo groups were observed in the 
Migraine Disability Assessment (MIDAS) questionnaire.43 
The MIDAS increased from start to end of the DB phase 
by 6 points in the placebo group while the topiramate group 
remained unchanged. The short form 12 general health ques-
tionnaire (SF-12)44 also showed a benefit in physical compo-
nent score for topiramate. Moreover, patients who received 
topiramate were more satisfied with the efficacy of therapy 
than those receiving placebo, whereas tolerability was similar 
in both treatment groups. The authors concluded that patients 
who discontinued therapy/received placebo had an increase 
in number of migraine days and a lower quality of life than 
patients still receiving topiramate. An interesting finding is 
that patients may also have a persistent benefit from topiramate 
even when discontinued, because the number of migraine days 
in most patients did not increase to pretreatment values.
Treatment of chronic migraine  
with topiramate
Headache is a very dynamic disease. The transition from epi-
sodic to chronic migraine is not uncommon. Approximately 
3% to 4%2,28,45,46 of the general population suffer from chronic 
daily headache that was defined by Silberstein et al as head-
ache lasting at least 4 hour per day with over 15 headache 
days per month.47 Chronic migraine (CM), chronic tension 
type headache (CTTH) and medication overuse headache 
(MOH) are the most common forms of chronic daily head-
ache.45 The most important risk factors for the development 
of CM are medication overuse and a high baseline attack 
frequency.48 The revised ICHD-2 defines CM as headaches 
occurring 15 days per month, with at least 8 attacks fulfill-
ing criteria for migraine without aura or responding to acute 
migraine medication (ie, triptans).49 Alternative definitions 
for CM are being discussed in the literature and final con-
sensus has not yet been reached.
Topiramate has been reported to reduce migraine fre-
quency in chronic migraine in some smaller clinical trials.50–52 
A pooled analysis performed by Limmroth et al concluded that 
preventive treatment with topiramate in patients with episodic 
migraine may reduce the risk of developing chronic forms 
of headache.53 Two large, randomized, double-blind, placebo-
controlled, parallel-group clinical trials were performed with 
topiramate in patients with CM. In general, these trials seem 
to be quite similar in design (CM with and without overuse, 
16-week DB phase, 100 mg topiramate target dose), but there 
are some key differences between these trials that must be 
considered when interpreting results. In the US trial with an 
intent-to-treat population of 306 patients total, the criteria for 
transformed migraine postulated by Silberstein and Lipton 
were used.54 No concomitant migraine preventive therapy was 
allowed and acute medication use was permitted on no more 
than 4 days a week. In contrast, the European trial55 used the 
unrevised criteria of ICHD-II,3 the intent to treat population 
was much smaller (n = 59), but the percentage of patients with 
an observed overuse during baseline was more than twice as 
high as in the US trial (78% vs 37.6%). The target dose in the 
European trial was also 100 mg/day, but flexible dose titration 
was allowed from 50 mg/day up to 200 mg/day. Medication 
overuse was allowed without any restriction, as was the intake 
of concomitant different migraine preventive therapy, except 
other antiepileptic drugs. Inclusion criteria and allowed rescue 
medication also differed between trials. The primary outcome 
variable was also different: in the US trial change from base-
line in mean monthly migraine/migrainous days over the 
entire DB phase was the main outcome measure, while in the 
European trial the change in mean monthly migraine days at 
the end of the DB phase was the main outcome variable. These 
differences have to be kept in mind when interpreting results. 
These studies are not completely comparable.
In the US trial a significant reduction in the mean monthly 
rate of migraine/migrainous days (6.4 ± 5.8), compared to 
placebo (4.7 ± 6.1; P = 0.010) and a mean reduction from 
baseline of migraine days per month (5.6 ± 6.0) compared 
to placebo (4.1 ± 6.1; P = 0.032) was found. In the European 
trial reduction in mean monthly migraine days (-3.5 ± 6.3) 
was found compared to placebo (0.2 ± 4.7; P = 0.02). In this 
analysis patients with medication overuse reported mean 
monthly migraine days reduction by 3.5 ± 7.1 days, which 
was significant compared to placebo with an increase of 0.8 ± 
4.8 days (P = 0.03). Similar data on medication overuse were 
unavailable from the US trial, but a secondary analysis was 
performed and showed a trend towards significant group differ-
ences (P = 0.059).56 In the European trial the responder rate of 
at least 50% in reduction of migraine days was significant for 
topiramate (22% vs 0% P = 0.012), but not in the US trial in 
which only the under 25% reduction in migraine/migrainous 
days responder rates showed significance.57 Patients’ disability 
and quality of life evaluation results were different in both 
trials. While HIT-6 and Migraine Specific Questionnaire 
(MSQ) total scores did not show a significant change com-
pared to placebo, the MIDAS score did in the European but 
not in the US trial. In contrast, in the US trial the role restric-
tive (RR) and emotional function (EF) domains of the MSQ 
showed significant differences in favor of topiramate.57 In the 
assessment of acute medication use, both trials were unable 
to show significant differences compared to placebo, but Neuropsychiatric Disease and Treatment 2010:6 24
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patients’ treatment contentment was better in patients receiving 
topiramate than in those receiving placebo in both trials.
Topiramate 100 mg/day seems to be effective in the 
treatment of chronic migraine. Lower dosage of 50 mg/day 
may also be effectivel.51 General treatment effect appears to 
be independent from medication overuse, thus it may not be 
necessary to withdraw patients with CM from medication 
overuse prior to a treatment attempt with topiramate.
Safety of topiramate treatment
Topiramate is generally considered to be safe and well 
tolerated in migraine treatment. The most common AE in 
the currently published large, controlled clinical trials were 
paresthesia, fatigue, anorexia and nausea. It seemed that 
AE occurred more often in patients treated with topiramate 
200 mg (TPM 200) than in those treated with lower doses. 
This observation was very distinct in the European trial; 
here dropout rates due to AE were much higher in the TPM 
200 group. No clinically important change in laboratory test 
results, vital signs or clinical examination was described in 
these trials. However, AE for cognitive symptoms (difficulty 
with memory, concentration/attention or speech problems) 
were seen in more than 10% of patients receiving topiramate, 
while only few patients receiving placebo were affected by 
such AE. This also seemed to be dose-dependent and more 
pronounced in the TPM 200 group. A pooled analysis includ-
ing 758 patients (386 on 100 mg/day topiramate, 372 on 
placebo) was performed.37 Paresthesia seems to be the most 
common AE with an incidence of 50.5%, but like most other 
AE more than 90% of patients suffering from it described it to 
be mild to moderate. Treatment is usually not necessary as the 
numbness and tingling are self-limiting, but use of potassium 
supplements may provide relief.58 Fatigue, which was the sec-
ond most common AE, was nearly as common in the placebo 
group as in the topiramate (TPM 15%, placebo 11.8%) group. 
Other common AE were anorexia (TPM 14.5%, placebo 
5.9%), upper respiratory tract infection (TPM 14%, placebo 
12.6%), nausea (TPM 13.2%, placebo 8.9%) and diarrhea 
(TPM 11.1%, placebo 4.3%). All other AE were reported 
in less than 10% of patients in the topiramate group, and 
included weight decrease, dizziness, taste perversion, hypo-
esthesia, insomnia, difficulty with memory, somnolence, 
language problems, difficulty with concentration/attention, 
and mood problems. Additional rare side effects of topiramate 
are depression, hallucinations or paranoia, vision problems 
that may be associated with eye pain, deep vein thrombo-
sis, hyperglycemia, hair loss, impotence, anorgasmia, and 
constipation. Rare narrow angle-closure glaucoma can occur 
early in treatment, and usually remits.59 At higher doses there 
is also a rare risk of oligohydrosis, which can result in poten-
tially fatal hyperthermia; this is more common in younger 
patients.60 Topiramate is a carbonic anhydrase inhibitor, which 
has an uncertain significance for migraine prevention, but 
has implications for AE. Hyperchloremic acidosis, rarely 
clinically significant, can occur in more than 10% of patients. 
Although most patients are asymptomatic, the acidosis can 
lead to an increased risk of renal calculi and osteomalacia, 
and thus may require blood monitoring of pH, bicarbonate and 
chloride. Nephrolithiasis occurs at a rate of 1% as a byproduct 
of this topiramate carbonic anhydrase inhibition.59
Generally, AE appear to be most pronounced at the begin-
ning of topiramate treatment within the first 2 months and often 
resolve over time. The onset of AE that were actually treatment 
limiting in large published trials tended to occur during the titra-
tion period.61 For example, the overall incidence of paresthesia 
was 50.5%, while the cumulative incidence was 45.5% on day 
28 and 49.5% on day 42 of the DB phase. The incidence of 
“any cognitive symptoms”, loss of appetite and fatigue also 
were most common within the titration phase.61 This led to the 
suggestion that if a patient has not experienced one of these AE 
within the first or second month, it will most likely not occur.
While weight gain is a common problem in patients 
receiving traditional migraine prophylaxis,62 one interest-
ing effect of topiramate is weight loss in many patients. It 
appears that this effect is limited, however, and that it is more 
pronounced in patients with a higher body mass index. In 
the pooled analysis by Bussone et al. the mean weight loss 
at the 6 months endpoint was -2.5 kg compared to 0.1 kg in 
the placebo group, but in overweight and obese patients it 
was -3.1 kg and 3 kg respectively.37
In the two studies investigating topiramate in a longer 
treatment period adverse events were similar to those reported 
in the shorter trials.40,41 Long-term treatment is not associated 
with greater risk for the patient, as most AE occur within 
the first 8 weeks of treatment. For interactions with other 
medications refer to Table 3.
Topiramate in pregnancy
The safety of topiramate in pregnancy is largely unknown. 
Only a few trials with small sample sizes have investigated 
this problem in human pregnancies.63–65 Topiramate is known 
to cross the human placenta and is secreted in the milk.66 In 
animal experiments it was found that topiramate is teratogenic 
in mice, rabbits, and rats.67 On a molecular basis topiramate 
inhibits histone deacetylases (HDACs) in human cells.68 
Conventional HDAC inhibitors mimic the defects related Neuropsychiatric Disease and Treatment 2010:6 25
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to prenatal exposure to valproic acid and the inhibition of 
HDACs by valproic acid was suggested to possibly represent 
the molecular starting point of its teratogenic risk.69 In 2007, 
a study investigating 52 pregnancies exposed to topiramate 
treatment showed a significant decrease in birth weights.64 
However, the authors concluded that the risk for structural 
defects was not increased in babies of patients treated with 
topiramate during pregnancy. As the investigated study popu-
lation was small, data do not permit a positive or negative 
conclusion. It should be kept in mind that lower birth weight 
is one of the expected effects of an HDAC inhibitor. In a 
recent analysis from the UK, 178 live births (resulting from 
203 pregnancies) of mothers who became pregnant during 
topiramate intake were analyzed.65 Only 70 of these patients 
received antiepileptic drug monotherapy. Their rate of major 
congenital malformations was comparable to those of other 
antiepileptic drugs (3 malformations in 70 live births). The 
rates in antiepileptic drug polytherapy with topiramate 
were even higher (especially in combinations containing 
valproate). So the rates of oral clefts were 11 times and those 
of hypospadias 14 times higher than background rates.
In conclusion, studies analyzing topiramate in pregnancy 
are small and rare. As all studies analyzed patients with 
epilepsy, sample-rates for topiramate monotherapy are even 
smaller. As there are hints for teratogenic risk in animal, 
molecular and clinical experiments, it must be concluded 
that the assessment of safety in pregnancy requires further 
investigations and treatment cannot be recommended 
at this time.
Topiramate in pediatric migraine
Migraine occurs in 10.6% of  children and adolescents between 
the ages of 5 and 15 years and 28% of adolescents between 
the ages of 15 and 19 years.70–75 Currently, no drugs have been 
approved by the Food and Drug Administration (FDA) for 
migraine prophylaxis in pediatric patients. Three randomized, 
controlled trials have been conducted, however, including a 
total of 212 children and adolescents between 6 and 17 years. 
Topiramate at 100 mg/day, but not 50 mg/day, significantly 
reduced the monthly migraine day rate from baseline versus 
placebo during the 12-week double-blind treatment phase.76–78 
Effective dosages reported throughout these trials ranged 
from 2 to 3 mg/kg/day and are much lower than the dosages 
usually required for the adjunctive treatment of epilepsy (5 to 
9 mg/kg/day) in young children. Safety and tolerability was 
comparable to reports from adult study populations. Most 
common side effects in children were weight loss (10.2%), 
anorexia (13%), abdominal pain (10.2%), difficulties in 
concentration, somnolence/sedation (8.3%), and paresthesia 
(8.3%). Side effects tended to decline over time and dropout 
rates due to side effects were very low in the different trials 
(range 0% to 6.3%). Assessment of  PedMIDAS (MIDAS 
for pediatric and adolescent patients) results showed a sig-
nificant decrease in absent school days and an improvement 
in the quality of life in these children.79
Patient preference
Few trials have directly investigated efficacy differences 
between different prophylactic treatment options in 
Table 3 Withdrawal rates in the three MiGr trials
  MIGR-001 Silberstein et al35 MIGR-002 Brandes et al36 MIGR-003 Diener et al19
Group (TPM dose in mg) 50 100 200 PLC 50 100 200 PLC 100 200 PrOP PLC
No of patients randomized 125 128 117 117 120 122 121 120 141 144 144 146
n withdrawal after  
randomization (withdrawal  
in % of patients randomized)
57  
(45.6)
45 
(35.2)
72 
(61.5)
48 
(66.7)
61 
(50.8)
59 
(48.4)
51 
(42.1)
57 
(47.5)
47 
(33.4)
79 
(54.9)
42 
(29.2)
47 
(32.2)
Withdrew due to Aes  
(% of overall withdrawal)
21 
(36.8)
24 
(53.3)
38 
(52.8)
11 
(22.9)
20 
(32.8)
32 
(54.2)
25 
(49.0)
14 
(24.6)
37 
(78.7)
63 
(79.7)
29 
(69.0)
15 
(31.9)
Withdrew due to lack  
of efficacy (% of overall  
withdrawal)
10 
(17.5)
6 
(13.3)
8 
(11.1)
21 
(43.7)
15 
(24.6)
11 
(18.6)
12 
(22.5)
21 
(36.8)
1 
(2.1)
2 
(2.5)
3 
(7.1)
13 
(27.7)
Withdrew due to subjects  
choice (% of overall)
10 
(17.5)
6 
(13.3)
8 
(11.1)
3 
(6.3)
8 
(13.1)
6 
(10.2)
5 
(9.8)
7 
(12.3)
5 
(10.6)
8 
(10.1)
3 
(7.1)
7 
(14.9)
No patients in intent  
to treat cohorts
117 125 112 115 117 120 117 114 139 143 143 143
No withdrawal after intent  
to treat
49  42  67  46  58  57  47  51  45  78  41  44 
Abbreviations: Ae, adverse events;   TMP, topiramate; PLC, placebo; PrOP, propranolol.Neuropsychiatric Disease and Treatment 2010:6 26
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migraine,80–83 which makes difficult an evidence-based 
decision on the drug of choice on the basis of efficacy. 
Patient preference, co-morbidities, contraindications and 
side effects will have to be considered for each individual 
patient. Topiramate generally is recommended in patients 
for whom beta-receptor-antagonists are contraindicated 
(eg, in chronic obstructive pulmonary disease or asthma) or 
unfavorable for the patient (eg, in obese patients, decreased 
sexual ability, hair loss). Topiramate may be preferred to 
other migraine preventive drugs with similar evidence for 
efficacy when patients may have an additive effect to their 
previously existing medication, eg, in patients with concomi-
tant epilepsy topiramate may be the preferred choice, while 
amitriptyline is not. In patients with migraine and obesity it 
may be a good choice because weight gain is a common side 
effect in classical migraine preventive treatment options such 
as beta-blockers, valproic acid and flunarizine. Especially in 
young women weight gain poses serious concern in terms of 
compliance. Some patients may suffer from more than one 
headache disorder, and because there is evidence that topira-
mate may be effective in the treatment of cluster headache84–86 
and other primary headache disorders it might be the drug 
of choice for these patients. Many further side effects and 
contraindications have to be taken into account in making 
a definite treatment decision (see Table 1 for an overview). 
Different forms of drug application may also be helpful 
in reaching a treatment decision in favor of topiramate, 
eg, topiramate is available in capsules and could be sprinkled 
on food if a patient has problems swallowing pills.
Combination of topiramate  
with other preventive drugs
As different migraine preventive drugs have different modes 
of action and additive effects might be suspected, combi-
nation therapy might help patients who are refractory to 
monotherapy.25,87 However, large controlled clinical trials 
are lacking in this regard. Some smaller studies have been 
conducted. In an open label trial testing the combination of 
topiramate with a beta-blocker in migraine patients previ-
ously resistant to at least two medications in monotherapy, 
58 patients received combined treatment.88 While 62% of 
patients showed at least moderate response (50% reduc-
tion in frequency), nearly half (44%) showed an excellent 
(75%) response to combination treatment. However, 
17% discontinued due to adverse events, although they had 
tolerated both drugs in monotherapy previously. The authors 
concluded that combination therapy is reasonable, consider-
ing the complementary mechanism of action, as a potential 
strategy in patients with refractory migraine. In a single-
center, double-blind, randomized, controlled trial investigat-
ing 73 patients with migraine headache,89 the effectiveness 
of amitriptyline and topiramate in the prevention of migraine 
attacks in comparison to monotherapy of each drug was 
evaluated. In all three treatment groups (amitriptyline alone; 
topriamate alone; amitriptyline and topiramate) improve-
ments in frequency, duration and severity of migraine were 
significant (all variables P  0.001). Improvement in depres-
sive state and consumption of medications was also reported 
(both variables P  0.001). Furthermore, patients receiving 
amitriptyline alone or the combination treatment had better 
depression scores than the topiramate monotherapy group. 
The authors concluded that the combination of amitriptyline 
and topiramate may be beneficial for patients with migraine 
and co-morbid depression. Although the combination of 
topiramate with other preventive treatment may be effective 
in treating refractory migraine, further research is needed.
Conclusion
There is sufficient scientific evidence that topiramate is effec-
tive in reducing migraine frequency at a dose of 100 mg/day 
in patients suffering from episodic migraine with or without 
aura. Topiramate 100 mg/day also appears to be effective in 
the treatment of CM. A lower dose of 50 mg/day may also 
be effective. General treatment effects appear to be indepen-
dent from medication overuse in CM, and thus it may not 
be necessary to withdraw patients from medication overuse 
prior to attempting treatment with topiramate. Data on treat-
ment periods longer than 14 months are still unavailable, but 
the trials performed give no reason to raise concern about 
efficacy or safety in long-term treatment. Topiramate is gen-
erally well tolerated with moderate side effects in migraine 
patients. Common side effects were paresthesias, fatigue, 
nausea, anorexia and weight loss within the first 8 weeks of 
treatment. Treatment in pediatric migraine (age 6 to 17 years) 
was proven safe and effective. Assessment of safety in preg-
nancy requires further investigations and cannot be recom-
mended at this time.
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